Pharming Group NV

Price Chart

Risk-Adjusted Performance

Also Listed On

Pharming Group NV (PHARM) Price Performance

Pharming Group NV (PHARM) trades on Euronext Amsterdam in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR1.49, up 0.17% from the previous close.

Over the past year, PHARM has traded between a low of EUR0.70 and a high of EUR1.78. The stock has gained 111.8% over this period. It is currently 16.1% below its 52-week high.

Pharming Group NV has a market capitalization of $1.05B, with a price-to-earnings ratio of 355.36.

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.